AU2018274545B2 - Combinations of MHC class Ib molecules and peptides for targeted therapeutic immunomodulation - Google Patents

Combinations of MHC class Ib molecules and peptides for targeted therapeutic immunomodulation Download PDF

Info

Publication number
AU2018274545B2
AU2018274545B2 AU2018274545A AU2018274545A AU2018274545B2 AU 2018274545 B2 AU2018274545 B2 AU 2018274545B2 AU 2018274545 A AU2018274545 A AU 2018274545A AU 2018274545 A AU2018274545 A AU 2018274545A AU 2018274545 B2 AU2018274545 B2 AU 2018274545B2
Authority
AU
Australia
Prior art keywords
gly
leu
ser
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018274545A
Other languages
English (en)
Other versions
AU2018274545A1 (en
Inventor
Valentin BRUTTEL
Jörg WISCHHUSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of AU2018274545A1 publication Critical patent/AU2018274545A1/en
Assigned to JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG reassignment JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG Request for Assignment Assignors: BRUTTEL, Valentin, JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
Application granted granted Critical
Publication of AU2018274545B2 publication Critical patent/AU2018274545B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018274545A 2017-05-23 2018-05-18 Combinations of MHC class Ib molecules and peptides for targeted therapeutic immunomodulation Active AU2018274545B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172444.6 2017-05-23
EP17172444 2017-05-23
PCT/EP2018/063100 WO2018215340A1 (en) 2017-05-23 2018-05-18 Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Publications (2)

Publication Number Publication Date
AU2018274545A1 AU2018274545A1 (en) 2019-12-05
AU2018274545B2 true AU2018274545B2 (en) 2023-09-21

Family

ID=58778895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018274545A Active AU2018274545B2 (en) 2017-05-23 2018-05-18 Combinations of MHC class Ib molecules and peptides for targeted therapeutic immunomodulation

Country Status (8)

Country Link
US (2) US20200157175A1 (enExample)
EP (1) EP3630809A1 (enExample)
JP (3) JP2020521000A (enExample)
KR (2) KR20250007053A (enExample)
CN (2) CN119185534A (enExample)
AU (1) AU2018274545B2 (enExample)
CA (1) CA3063959A1 (enExample)
WO (1) WO2018215340A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112941030B (zh) * 2021-01-25 2023-08-08 吉林大学 一种抗原特异性Treg及其制备方法和应用
EP4249062A1 (en) 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
WO2023180546A1 (en) 2022-03-24 2023-09-28 Julius-Maximilians-Universität Würzburg Mho ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
JP2025510149A (ja) 2022-03-24 2025-04-14 ユリウス－マクシミリアンス－ウニヴェルジテート ヴュルツブルク １型糖尿病の新規治療法としてのＭＨＣ Ｉｂ仲介膵島抗原特異的免疫抑制
EP4249506A1 (en) 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
TW202519540A (zh) 2023-09-22 2025-05-16 德國符茲堡大學 MHC Ib媒介之髓磷脂特異性免疫抑制作為用於多發性硬化症及MOG抗體疾病之新穎治療
TW202530251A (zh) 2023-09-22 2025-08-01 德國符茲堡大學 ＭＨＣ Ｉｂ媒介之水通道蛋白４（ＡＱＰ４）特異性免疫抑制作為用於ＮＭＯ之新穎治療
WO2025061918A1 (en) 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131575A1 (en) * 2006-05-12 2007-11-22 Fondazione Centro San Raffaele Del Monte Tabor Tolerogenic dendritic cells, method for their production and uses thereof
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
US20150250862A1 (en) * 2012-09-28 2015-09-10 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054688B1 (fr) 1998-02-20 2004-06-30 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
FR2794977B1 (fr) 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
EP3269384A1 (en) * 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
WO2009100135A2 (en) * 2008-02-04 2009-08-13 Medical College Georgia Research Institute, Inc. Hla-g compositions and methods of use thereof
EP2184297A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
CA2959821C (en) * 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131575A1 (en) * 2006-05-12 2007-11-22 Fondazione Centro San Raffaele Del Monte Tabor Tolerogenic dendritic cells, method for their production and uses thereof
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
US20150250862A1 (en) * 2012-09-28 2015-09-10 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof

Also Published As

Publication number Publication date
KR102748741B1 (ko) 2024-12-31
KR20250007053A (ko) 2025-01-13
CN110945019A (zh) 2020-03-31
AU2018274545A1 (en) 2019-12-05
JP2020521000A (ja) 2020-07-16
JP2023052647A (ja) 2023-04-11
CN119185534A (zh) 2024-12-27
US20200157175A1 (en) 2020-05-21
CN110945019B (zh) 2025-04-04
KR20200021475A (ko) 2020-02-28
CA3063959A1 (en) 2018-11-29
JP2025072445A (ja) 2025-05-09
US20230416338A1 (en) 2023-12-28
EP3630809A1 (en) 2020-04-08
WO2018215340A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
US20230416338A1 (en) Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
TWI822726B (zh) Ｎｙｅｓｏ ｔ細胞受體
JP7202512B2 (ja) Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質
Stone et al. Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies
CN101287831B (zh) T细胞受体和编码该受体的核酸
WO2016177339A1 (zh) 识别ny-eso-1抗原短肽的t细胞受体
JP2019517790A (ja) ＴＧＦβＲＩＩのフレームシフト変異体を認識するＴ細胞受容体
JP2017522859A (ja) グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用
CN109575121B (zh) 识别afp抗原短肽的t细胞受体
CN106831978A (zh) 识别prame抗原的t细胞受体
CN110272482B (zh) 识别prame抗原短肽的t细胞受体
WO2016177195A1 (zh) 识别rhamm抗原短肽的t细胞受体
TW202140532A (zh) 一種辨識afp的t細胞受體及其編碼序列
Housseau et al. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
CN108659114B (zh) 识别pasd1抗原短肽的tcr
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
NL2034658B1 (en) TIMP3-derived TEIPP neoantigens and uses thereof
CN110272483B (zh) 识别sage1抗原短肽的t细胞受体
JP2024537353A (ja) 改変された結合タンパク質及びその治療上の使用
JP2025009531A (ja) Ｔ細胞受容体およびその利用
Renkvist Functional characterisation of the T cell mediated anti-tumour response in a melanoma patient: identification of a HLA-DRβ1* 10011 restricted unique antigen
Borras-Cuesta et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG

Free format text: FORMER APPLICANT(S): BRUTTEL, VALENTIN; JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG

FGA Letters patent sealed or granted (standard patent)